Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2016
Price : $35 *
At a glance
- Drugs Fenofibrate (Primary)
- Indications Metabolic syndrome
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
- 25 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2014.
- 25 Oct 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2014.
- 19 Mar 2014 New trial record